Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today we highlight:
- an article reporting how the Supreme Court is “set to start a four-week recess . . . without having ruled on pending challenges to most of the duties Trump has imposed over the last year”;
- an article discussing how the Supreme Court agreed to hear a “skinny labels” patent fight that could have “broad consequences for generic drug makers”; and
- a blog post predicting the Patent Trial and Appeal Board “is likely to undergo a dramatic transformation in 2026 based upon the convergence of two parallel developments.”
